Best treatment practices for pachyonychia congenita

I Goldberg, D Fruchter, A Meilick… - Journal of the …, 2014 - Wiley Online Library
I Goldberg, D Fruchter, A Meilick, ME Schwartz, E Sprecher
Journal of the European Academy of Dermatology and Venereology, 2014Wiley Online Library
Background Numerous therapeutic modalities have been proposed to treat the
manifestations of pachyonychia congenita (PC). While research hopes lie with molecular
therapies, patients are in need of answers regarding the efficacy of conventional treatments.
Aim of the study To determine patients' experience and preferences regarding conventional
treatments for PC. Methods The study population included 120 PC patients from 20
countries. The study was based on a patient survey developed by physicians and …
Background
Numerous therapeutic modalities have been proposed to treat the manifestations of pachyonychia congenita (PC). While research hopes lie with molecular therapies, patients are in need of answers regarding the efficacy of conventional treatments.
Aim of the study
To determine patients' experience and preferences regarding conventional treatments for PC.
Methods
The study population included 120 PC patients from 20 countries. The study was based on a patient survey developed by physicians and researchers from the International Pachyonychia Congenita Consortium and conducted via the internet. Using an effectiveness scale of 1 to 5, the patients were asked to grade treatments for different manifestations, including keratoderma, cysts, follicular hyperkeratosis, fingernail and toenail involvement.
Results
Patients reported surgical treatments being most effective for cysts and mechanical treatments the most effective conventional therapeutic approach for all other investigated manifestations. The other conventional medical treatments were found to be non‐effective to only slightly effective. Among patients with keratoderma, older people were more likely to report beneficial effect from mechanical treatments (P = 0.04), topical retinoids (P = 0.04) and topical steroids (P = 0.02). Likewise, females were more inclined to report filing and grinding beneficial than males (P = 0.02). Finally, carriers of KRT16 and KRT6a were more likely to benefit from keratolytics than carriers of mutations in KRT17 (P = 0.04).
Conclusions
None of the currently available therapeutic options for PC are ideal, although they provide some relief, with mechanical/surgical options being preferred over medical therapies. These results emphasize the need for more efficient and targeted therapies.
Wiley Online Library